Evidence map›Paper›PMID 32476815›Full record

ReviewMolecular vision2020

Review: Role of cAMP signaling in diabetic retinopathy.

Jena J Steinle

Open access · greenAbstract readReview
In one paragraph

Review in Molecular vision, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Prostaglandin EFrontiers in pharmacology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jena J SteinleDepartment of Ophthalmology, Visual, and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI.
Wayne State University · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
VISION RESEARCH--COREP30EY004068 · NEI · WAYNE STATE UNIVERSITY · PI LINDA D HAZLETT · 1985 to 2026
$13.2M
Inhibition of HMGB1 as a protective mechanism against diabetic retinopathyR01EY028442 · NEI · WAYNE STATE UNIVERSITY · PI STEINLE, JENA J · 2018 to 2021
$1.8M
PKA and Epac1 inhibit TLR4 to protect the diabetic retinaR01EY030284 · NEI · WAYNE STATE UNIVERSITY · PI STEINLE, JENA J · 2020 to 2024
$1.7M
NEI NIH HHS P30 EY004068NEI NIH HHS R01 EY028442NEI NIH HHS R01 EY030284NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

Despite decades of research, diabetic retinopathy remains the leading cause of blindness in working age adults. Treatments for early phases for the disease remain elusive. One pathway that appears to regulate neuronal, vascular, and inflammatory components of diabetic retinopathy is the cyclic adenosine 3', 5'-monophosphate (cAMP) pathway. In this review, we discuss the current literature on cAMP actions on the retina, with a focus on neurovascular changes commonly associated with preproliferative diabetic retinopathy models.

Indexed as

AnimalsCyclic AMPDiabetes MellitusDiabetic RetinopathyHumansInflammationNeovascularization, PathologicNeuronsRetinaSignal TransductionCyclic AMP

Identifiers

PMID32476815
PMCPMC7245604
OpenAlexW3031855414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.